Navigation Links
Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011
Date:4/12/2011

NEW YORK, April 12, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 – Volume I 2011

http://www.reportlinker.com/p0479813/Gastric-Cancer---Global-Drug-Forecasts-and-Treatment-Analysis-to-2020-–-Volume-I-2011.html

Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 – Volume I 2011

Summary

GlobalData, the industry analysis specialist, has released its new report, "Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 – Volume I 2011". The report is an essential source of information and analysis on the global gastric cancer therapeutics market. The report provides comprehensive information on gastric cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global gastric cancer therapeutics market. It analyses the treatment usage patterns in the global gastric cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global gastric cancer sector. It quantifies the unmet need in the global gastric cancer therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The Scope of the report includes:

- An overview of gastric cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.

- Annualized global gastric cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020.

- Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France Japan and BRIC countries that include Brazil, Russia, India and China

- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.

- Competitor assessment including drug launch analysis and drug sales forecasts.

- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, product positioning and drug sales forecast.

- Analysis of unmet need in the market and target product profile including opportunity for target product.

- Technology trends analytic framework to assess strength of pipeline.

- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include vascular endothelial growth factor (VGEF) inhibitors, tubulin inhibitors, topoisomerase inhibitors, mammalian target of rapamycin (mTOR) inhibitors and DNA synthesis inhibitors.

- Clinical trials mapping of trials for gastric cancer in different regions.

- An overview of the most promising drugs' including clinical study details, efficacy, safety, collaboration agreements, marketing rights, and launch analysis and drug sales forecasts to 2020.

- Analysis of the current and future market competition in the global Gastric Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key market players covered include Sanofi-aventis, Novartis AG, GlaxoSmithKline, Hoffmann-La Roche Ltd., Eli Lilly and Company, Otsuka and Merck KGaA.

- Analysis of licensing agreements during 2009-2010 in the gastric cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.

- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.

- Direct quotes from key opinion leaders (KOL) or physicians in the gastric cancer therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop business strategies and perform superior market quantification analysis by

- Understanding the trends shaping and driving the global gastric cancer therapeutics market.

- Understanding treatment preferences of physicians in disease state and across treatment flow.

- Accessing market sizing, forecasts and quantified growth opportunities in the global gastric cancer therapeutics market till 2020.

- Quantifying patient population in the global gastric cancer market to better design product pricing & launch plans.

- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by

- Performing benchmarking analysis and growth opportunities against currently marketed products

- Identifying market entry points based on safety, efficacy, and pricing parameters.

- Assessing competitiveness of products in market by understanding the strength and weakness of current competition.

- Develop and design your in-licensing and out-licensing strategies by

- taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.

- Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.

- Track drug sales in the global gastric cancer therapeutics market from 2001 to 2020

- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

- What's the next big thing in the global gastric cancer therapeutics market landscape? Identify, understand and capitalize

1 Table of contents

1 Table of contents 3

1.1 List of Tables 7

1.2 List of Figures 10

2 Introduction 14

2.1 Disease Overview 14

2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System 14

2.2 Epidemiology 16

2.3 Etiology 16

2.4 Symptoms 17

2.4.1 Initial Symptoms 17

2.4.2 Symptoms Observed in Later Stages 17

2.5 Diagnosis 18

2.5.1 Fecal Occult Blood Test (FOBT) 18

2.5.2 X-ray of Upper Gastrointestinal Tract (GI Series) 19

2.5.3 Endoscopy (Gastroscopy) 19

2.5.4 Computed Tomography (CT) 20

2.5.5 Biopsy 20

2.6 Pathology 20

2.6.1 Grading 21

2.7 Prognosis 22

2.8 Treatment 22

2.8.1 Gastric Cancer Treatment Options 23

2.9 Treatment Guidelines 27

2.10 GlobalData Report Guidance 28

3 Market Characterization 29

3.1 Global 29

3.1.1 Market Size 29

3.1.2 Drivers and Restraints 37

3.1.3 Forecasts 39

3.1.4 Drug Sales 46

3.2 The US 50

3.2.1 Market Size 50

3.2.2 Drivers and Restraints 56

3.2.3 Forecasts 59

3.2.4 Drug Sales 65

3.2.5 Pricing and Reimbursements 68

3.3 The UK 69

3.3.1 Market Size 69

3.3.2 Drivers and Restraints 75

3.3.3 Impact on the Market 77

3.3.4 Forecasts 78

3.3.5 Drug Sales 84

3.3.6 Pricing and Reimbursements 87

3.4 Germany 88

3.4.1 Market Size 88

3.4.2 Drivers and Restraints 94

3.4.3 Impact on the Market 96

3.4.4 Forecasts 97

3.4.5 Drug Sales 103

3.4.6 Pricing and Reimbursements 106

3.5 France 107

3.5.1 Market Size 107

3.5.2 Drivers and Restraints 113

3.5.3 Impact on the Market 114

3.5.4 Forecasts 115

3.5.5 Drug Sales 121

3.5.6 Pricing and Reimbursements 124

3.6 Italy 125

3.6.1 Market Size 125

3.6.2 Drivers and Restraints 131

3.6.3 Impact on the Market 133

3.6.4 Forecasts 134

3.6.5 Drug Sales 140

3.6.6 Pricing and Reimbursements 143

3.7 Spain 144

3.7.1 Market Size 144

3.7.2 Drivers and Restraints 150

3.7.3 Impact on the Market 152

3.7.4 Forecasts 153

3.7.5 Drug Sales 159

3.7.6 Pricing and Reimbursements 162

3.8 Japan 163

3.8.1 Market Size 163

3.8.2 Drivers and Restraints 168

3.8.3 Impact on the Market 169

3.8.4 Forecasts 170

3.8.5 Future Impact 175

3.8.6 Drug Sales 176

3.8.7 Pricing and Reimbursements 179

3.9 Brazil 180

3.9.1 Market Size 180

3.9.2 Drivers and Restraints 185

3.9.3 Impact on the Market 186

3.9.4 Forecasts 187

3.9.5 Future Impact 193

3.10 Russia 194

3.10.1 Market Size 194

3.10.2 Drivers and Restraints 199

3.10.3 Impact on the Market 200

3.10.4 Forecasts 201

3.10.5 Future Impact 206

3.11 India 207

3.11.1 Market Size (2002-2010) 207

3.11.2 Drivers and Restraints 212

3.11.3 Impact on the Market 213

3.11.4 Forecasts (2010-2020) 214

3.11.5 Future Impact 219

3.12 China 220

3.12.1 Market Size (2002-2010) 220

3.12.2 Drivers and Restraints 225

3.12.3 Impact on the Market 226

3.12.4 Impact on the Market 226

3.12.5 Forecasts (2010-2020) 227

3.12.6 Future Impact 232

3.13 Key Takeaway 232

4 Gastric Cancer Market: Competitive Assessment 233

4.1 Strategic Competitor Assessment 233

4.1.1 Overview 233

4.1.2 Benchmarking 234

4.1.3 Current Competitor Assessment 236

4.2 Launch Analysis and Sales Forecasts 238

4.3 Product Profiles of Major Marketed Drugs in the Gastric Cancer Market 239

4.3.1 Herceptin (trastuzumab) 239

4.3.2 Taxotere (docetaxel) 242

4.3.3 Teysuno 243

4.3.4 Xeloda 245

4.4 Key Takeaway 246

5 Gastric Cancer Market: Pipeline Assessment 247

5.1 Overview 247

5.2 Pipeline Analysis by Phase of Development 247

5.3 Pipeline by Mechanism of Action 248

5.4 Strategic Pipeline Assessment 249

5.4.1 Technology Trends Analytic Framework 249

5.5 Gastric Cancer – Promising Drugs Under Clinical Development 251

5.6 Partners in Development 252

5.6.1 Licensing Agreements 252

5.6.2 Research and Development Partnership Agreements 253

5.6.3 Technology and Diagnostic Agreements 255

5.7 Molecule Profile for Promising Drugs Under Clinical Development 256

5.7.1 Tykerb (Lapatinib) 256

5.7.2 Afinitor (Everolimus) 257

5.7.3 IMC-1121B (ramucirumab) 257

5.7.4 Cetuximab plus capecitabine and cisplatin 258

5.7.5 Apatinib (YN968DI) 258

5.8 Key Takeaway 259

6 Clinical Trials Mapping 260

6.1 Clinical Trials 260

6.1.1 Clinical Trials by Status 260

6.1.2 Clinical Trials by Country 261

6.1.3 Clinical Trials by Phase 262

6.1.4 Clinical Trials by Sponsor Type 263

6.1.5 Clinical Trials – Leading Sponsors 264

6.1.6 Clinical Trials – Leading Company Sponsors by Phase 265

6.2 Patient Recruitment 266

7 Opportunity and Unmet Need 267

7.1 Unmet Need 267

7.2 Opportunity for Target Products 269

7.3 Key Takeaway 270

8 Strategic Assessment 271

8.1 Key Events Impacting the Future Market 271

8.2 Market Impact Analysis 272

8.3 Future Market Scenario 272

9 Gastric Cancer Market: Future Players 274

9.1 Introduction 274

9.2 Novartis AG 275

9.2.1 Business Description 275

9.2.2 Financial Overview 276

9.2.3 Gastric Cancer Pipeline 276

9.2.4 SWOT Analysis 277

9.3 GlaxoSmithKline 283

9.3.1 Business Description 283

9.3.2 Financial Overview 284

9.3.3 Gastric Cancer Pipeline 284

9.3.4 SWOT Analysis 285

9.4 Hoffmann-La Roche Ltd. 291

9.4.1 Business Description 291

9.4.2 Financial Performance 293

9.4.3 Gastric Cancer Pipeline 293

9.4.4 SWOT Analysis 294

9.5 Eli Lilly and Company 298

9.5.1 Business Description 298

9.5.2 Financial Overview 300

9.5.3 Gastric Cancer Pipeline 300

9.5.4 SWOT Analysis 301

9.6 Otsuka Holdings Co., Ltd./Otsuka Pharmaceutical Co., Ltd. 306

9.6.1 Business Description 306

9.6.2 Gastric Cancer Products 306

9.7 Merck KGaA 307

9.7.1 Business Description 307

9.7.2 Financial Overview 307

9.7.3 Gastric Cancer Pipeline 307

9.7.4 SWOT Analysis 308

10 Gastric Cancer Market: Players in the Gastric Cancer Market 313

10.1 Sanofi-aventis 313

10.1.1 Business Description 313

10.1.2 Financial Overview 315

10.1.3 SWOT Analysis 315

10.1.4 Oncology Focus 320

11 M&A Analysis 321

11.1 Key Highlights 321

11.2 Key Deals' Analysis 323

11.2.1 CrystalGenomics Completes Merger with BexPharm 323

11.2.2 Astellas Pharma Acquires OSI Pharmaceuticals 323

11.2.3 Eli Lilly Acquires ImClone 323

11.2.4 Roche Acquires Additional 9.8% Stake in Chugai Pharmaceuticals 324

12 Expert Opinion 325

12.1 The US 325

12.2 Germany 326

12.3 Italy 326

12.4 Spain 327

12.5 Japan 328

13 Appendix 329

13.1 Market Definitions 329

13.2 Abbreviations 329

13.3 Research Methodology 330

13.3.1 Coverage 330

13.3.2 Secondary Research 331

13.3.3 Forecasting 331

13.3.4 Primary Research 334

13.3.5 Expert Panel validation 334

13.3.6 Contact Us 334

13.3.7 Disclaimer 334

13.3.8 Sources 335

1.1 List of Tables

Table 1: Gastric Cancer Therapeutics Market, Global, Staging of Gastric Cancer, 2010 15

Table 2: Gastric Cancer Therapeutics Market, Global, Risk Factors, 2010 16

Table 3: Gastric Cancer, Global, Results of GI Series X-ray, 2010 19

Table 4: Gastric Cancer, Global, WHO Classification of Gastric Carcinomas, 2010 21

Table 5: Gastric Cancer, Global, Five Year Relative Survival by Stage, 2010 22

Table 6: Gastric Cancer, Global, Illustration of Subtotal and Total Gastrectomy, 2011 25

Table 7: Gastric Cancer, Global, Sales Value ($m), 2002-2010 29

Table 8: Gastric Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 2002-2010 31

Table 9: Gastric Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 33

Table 10: Gastric Cancer Therapeutics Market, Global, Patient Volume ('000s), 2002-2010 34

Table 11: Gastric Cancer Therapeutics Market, Global, Treatment Usage Patterns ('000s), 2002-2010 35

Table 12: Gastric Cancer Therapeutics Market, Global, Sales Value ($m), 2010-2020 39

Table 13: Gastric Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 2010-2020 40

Table 14: Gastric Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2020 41

Table 15: Gastric Cancer Therapeutics Market, Global, Patient Volume ('000s), 2010-2020 42

Table 16: Gastric Cancer Therapeutics Market, Global, Treatment Usage Patterns ('000s), 2010-2020 43

Table 17: Gastric Cancer Therapeutics Market, Global, Gastric Cancer Drug Sales ($m), 2002-2010 47

Table 18: Gastric Cancer Therapeutics Market, Global, Gastric Cancer Drug Sales ($m), 2011-2020 48

Table 19: Gastric Cancer Therapeutics Market, the US, Sales Value ($bn), 2002-2010 50

Table 20: Gastric Cancer Therapeutics Market, the US, Annual Cost of Therapy ($), 2002-2010 51

Table 21: Gastric Cancer Therapeutics Market, the US, Patient Volume (Absolute), 2002-2010 52

Table 22: Gastric Cancer Therapeutics Market, the US, Treatment Usage Patterns ('000s), 2002-2010 54

Table 23: Gastric Cancer Therapeutics Market, the US, Sales Value ($m), 2010-2020 59

Table 24: Gastric Cancer Therapeutics Market, the US, Annual Cost of Therapy ($), 2010-2020 60

Table 25: Gastric Cancer Therapeutics Market, the US, Patient Volume (Absolute), 2010-2020 61

Table 26: Gastric Cancer Therapeutics Market, the US, Treatment Usage Patterns ('000s), 2010-2020 62

Table 27: Gastric Cancer Therapeutics Market, the US, Gastric Cancer Drug Sales ($m), 2002-2010 66

Table 28: Gastric Cancer Therapeutics Market, the US, Gastric Cancer Drug Sales ($m), 2011-2020 67

Table 29: Gastric Cancer Therapeutics Market, the UK, Sales Value ($m), 2002-2010 69

Table 30: Gastric Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2002-2010 71

Table 31: Gastric Cancer Therapeutics Market, the UK, Patient Volume (Absolute), 2002-2010 72

Table 32: Gastric Cancer Therapeutics Market, the UK, Treatment Usage Patterns ('000s), 2002-2010 73

Table 33: Gastric Cancer Therapeutics Market, the UK, Sales Value ($m), 2010-2020 78

Table 34: Gastric Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2010-2020 79

Table 35: Gastric Cancer Therapeutics Market, the UK, Patient Volume (Absolute), 2010-2020 80

Table 36: Gastric Cancer Therapeutics Market, the UK, Treatment Usage Patterns ('000s), 2010-2020 81

Table 37: Gastric Cancer Therapeutics Market, the UK, Gastric Cancer Drug Sales ($m), 2002-2010 85

Table 38: Gastric Cancer Therapeutics Market, the UK, Gastric Cancer Drug Sales ($m), 2011-2020 86

Table 39: Gastric Cancer Therapeutics Market, Germany, Sales Value ($m), 2002-2010 88

Table 40: Gastric Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002-2010 90

Table 41: Gastric Cancer Therapeutics Market, Germany, Patient Volume (Absolute), 2002-2010 91

Table 42: Gastric Cancer Therapeutics Market, Germany, Treatment Usage Patterns ('000s), 2002-2010 92

Table 43: Gastric Cancer Therapeutics Market, Germany, Sales Value ($m), 2010-2020 97

Table 44: Gastric Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2010-2020 98

Table 45: Gastric Cancer Therapeutics Market, Germany, Patient Volume (Absolute), 2010-2020 99

Table 46: Gastric Cancer Therapeutics Market, Germany, Treatment Usage Patterns ('000s), 2010-2020 100

Table 47: Gastric Cancer Therapeutics Market, Germany, Gastric Cancer Drug Sales ($m), 2002-2010 104

Table 48: Gastric Cancer Therapeutics Market, Germany, Gastric Cancer Drug Sales ($m), 2011-2020 105

Table 49: Gastric Cancer Therapeutics Market, France, Sales Value ($m), 2002-2010 107

Table 50: Gastric Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2002-2010 109

Table 51: Gastric Cancer Therapeutics Market, France, Patient Volume (Absolute), 2002-2010 110

Table 52: Gastric Cancer Therapeutics Market, France, Treatment Usage Patterns ('000s), 2002-2010 111

Table 53: Gastric Cancer Therapeutics Market, France, Sales Value ($m), 2010-2020 115

Table 54: Gastric Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2010-2020 116

Table 55: Gastric Cancer Therapeutics Market, France, Patient Volume (Absolute), 2010-2020 117

Table 56: Gastric Cancer Therapeutics Market, France, Treatment Usage Patterns ('000s), 2010-2020 118

Table 57: Gastric Cancer Therapeutics Market, France, Gastric Cancer Drug Sales ($m), 2002-2010 122

Table 58: Gastric Cancer Therapeutics Market, France, Gastric Cancer Drug Sales ($m), 2011-2020 123

Table 59: Gastric Cancer Therapeutics Market, Italy, Sales Value ($m), 2002-2010 125

Table 60: Gastric Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002-2010 127

Table 61: Gastric Cancer Therapeutics Market, Italy, Patient Volume (Absolute), 2002-2010 128

Table 62: Gastric Cancer Therapeutics Market, Italy, Treatment Usage Patterns ('000s), 2002-2010 129

Table 63: Gastric Cancer Therapeutics Market, Italy, Sales Value ($m), 2010-2020 134

Table 64: Gastric Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2010-2020 135

Table 65: Gastric Cancer Therapeutics Market, Italy, Patient Volume (Absolute), 2010-2020 136

Table 66: Gastric Cancer Therapeutics Market, Italy, Treatment Usage Patterns ('000s), 2010-2020 137

Table 67: Gastric Cancer Therapeutics Market, Italy, Gastric Cancer Drug Sales ($m), 2002-2010 141

Table 68: Gastric Cancer Therapeutics Market, Italy, Gastric Cancer Drug Sales ($m), 2011-2020 142

Table 69: Gastric Cancer Therapeutics Market, Spain, Sales Value ($m), 2002-2010 144

Table 70: Gastric Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002-2010 146

Table 71: Gastric Cancer Therapeutics Market, Spain, Patient Volume (Absolute), 2002-2010 147

Table 72: Gastric Cancer Therapeutics Market, Spain, Treatment Usage Patterns ('000s), 2002-2010 148

Table 73: Gastric Cancer Therapeutics Market, Spain, Sales Value ($m), 2010-2020 153

Table 74: Gastric Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2010-2020 154

Table 75: Gastric Cancer Therapeutics Market, Spain, Patient Volume (Absolute), 2010-2020 155

Table 76: Gastric Cancer Therapeutics Market, Spain, Treatment Usage Patterns ('000s), 2010-2020 156

Table 77: Gastric Cancer Therapeutics Market, Spain, Gastric Cancer Drug Sales ($m), 2002-2010 160

Table 78: Gastric Cancer Therapeutics Market, Spain, Gastric Cancer Drug Sales ($m), 2011-2020 161

Table 79: Gastric Cancer Therapeutics Market, Japan, Sales Value ($m), 2002-2010 163

Table 80: Gastric Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2010 164

Table 81: Gastric Cancer Therapeutics Market, Japan, Patient Volume (Absolute), 2002-2010 165

Table 82: Gastric Cancer Therapeutics Market, Japan, Treatment Usage Patterns ('000s), 2002-2010 166

Table 83: Gastric Cancer Therapeutics Market, Japan, Sales Value ($m), 2010-2020 170

Table 84: Gastric Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2010-2020 171

Table 85: Gastric Cancer Therapeutics Market, Japan, Patient Volume (Absolute), 2010-2020 172

Table 86: Gastric Cancer Therapeutics Market, Japan, Treatment Usage Patterns ('000s), 2010-2020 173

Table 87: Gastric Cancer Therapeutics Market, Japan, Gastric Cancer Drug Sales ($m), 2002-2010 177

Table 88: Gastric Cancer Therapeutics Market, Japan, Gastric Cancer Drug Sales ($m), 2011-2020 178

Table 89: Gastric Cancer Therapeutics Market, Brazil, Sales Value ($m), 2002-2010 180

Table 90: Gastric Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002-2010 181

Table 91: Gastric Cancer Therapeutics Market, Brazil, Patient Volume (Absolute), 2002-2010 182

Table 92: Gastric Cancer Therapeutics Market, Brazil, Treatment Usage Patterns ('000s), 2002-2010 183

Table 93: Gastric Cancer Therapeutics Market, Brazil, Sales Value ($m), 2010-2020 187

Table 94: Gastric Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2010-2020 188

Table 95: Gastric Cancer, Brazil, Patient Volume (Absolute), 2010-2020 189

Table 96: Gastric Cancer Therapeutics Market, Brazil, Treatment Usage Patterns ('000s), 2010-2020 191

Table 97: Gastric Cancer, Russia, Sales Value ($m), 2002-2010 194

Table 98: Gastric Cancer, Russia, Annual Cost of Therapy ($), 2002-2010 195

Table 99: Gastric Cancer, Russia, Patient Volume (Absolute), 2002-2010 196

Table 100: Gastric Cancer, Russia, Treatment Usage Patterns, 2002-2010 197

Table 101: Gastric Cancer, Russia, Sales Value ($m), 2010-2020 201

Table 102: Gastric Cancer, Russia, Annual Cost of Therapy ($), 2010-2020 202

Table 103: Gastric Cancer, Russia, Patient Volume (Absolute), 2010-2020 203

Table 104: Gastric Cancer, Russia, Treatment Usage Patterns, 2010-2020 204

Table 105: Gastric Cancer, India, Sales Value ($m), 2002-2010 207

Table 106: Gastric Cancer, India, Annual Cost of Therapy ($), 2002-2010 208

Table 107: Gastric Cancer, India, Patient Volume (Absolute), 2002-2010 209

Table 108: Gastric Cancer, India, Treatment Usage Patterns, 2002-2010 210

Table 109: Gastric Cancer, India, Sales Value ($m), 2010-2020 214

Table 110: Gastric Cancer, India, Annual Cost of Therapy ($), 2010-2020 215

Table 111: Gastric Cancer, India, Patient Volume (Absolute), 2010-2020 216

Table 112: Gastric Cancer, India, Treatment Usage Patterns, 2010-2020 217

Table 113: Gastric Cancer, China, Sales Value ($m), 2002-2010 220

Table 114: Gastric Cancer, China, Annual Cost of Therapy ($), 2002-2010 221

Table 115: Gastric Cancer, China, Patient Volume (Absolute), 2002-2010 222

Table 116: Gastric Cancer, China, Treatment Usage Patterns, 2002-2010 223

Table 117: Gastric Cancer, China, Sales Value ($m), 2010-2020 227

Table 118: Gastric Cancer, China, Annual Cost of Therapy ($), 2010-2020 228

Table 119: Gastric Cancer, China, Patient Volume (Absolute), 2010-2020 229

Table 120: Gastric Cancer, China, Treatment Usage Patterns, 2010-2020 230

Table 121: Gastric Cancer, Global, Clinical Endpoints for Benchmarking, 2010 234

Table 122: Gastric Cancer, Global, Chemotherapy, Safety Profile of Approved Treatment, 2010 235

Table 123: Gastric Cancer, Global, Benchmarking of Major Marketed Products, 2010 239

Table 124: Gastric Cancer – Most Promising Drugs Under Clinical Development, 2010 251

Table 125: Gastric Cancer, Global, Licensing Agreements, 2007-2010 252

Table 126:Gastric Cancer, Global, Research and Development Partnership Agreements, 2009-2010 253

Table 127: Gastric Cancer, Global, Technology and Diagnostic Agreements, 2009-2010 255

Table 128: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Status, January 2011 260

Table 129: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Country, January 2011 261

Table 130: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Phase, January 2011 262

Table 131: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, January 2011 263

Table 132:Gastric Cancer Therapeutics Market, Global, Clinical Trials, Leading Sponsors, January 2011 264

Table 133:Gastric Cancer Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, January 2011 265

Table 134:Gastric Cancer Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, January 2011 266

Table 135: Novartis AG – Clinical Pipeline for Gastric Cancer, 2010 276

Table 136: GlaxoSmithKline – Clinical Pipeline for Gastric Cancer, 2011 284

Table 137: Roche – Clinical Pipeline for Gastric Cancer, 2011 293

Table 138: Eli Lilly and Company – Clinical Pipeline for Gastric Cancer, 2011 300

Table 139: Otsuka Holdings Co., Ltd. – Clinical Pipeline for Gastric Cancer, 2011 306

Table 140: Merck KGaA – Clinical Pipeline for Gastric Cancer, 2011 307

Table 141: Gastric Cancer, Global, M&A Deals, 2010 322

1.2 List of Figures

Figure 1: Gastric Cancer, Global, Illustration of Subtotal and Total Gastrectomy, 2011 23

Figure 2: Gastric Cancer Therapeutics Market, Global, Treatment Guidelines, 2010 27

Figure 3: Gastric Cancer, Global, Sales Value ($m), 2002-2010 29

Figure 4: Gastric Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 2002-2010 31

Figure 5: Gastric Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 33

Figure 6: Gastric Cancer Therapeutics Market, Global, Patient Volume ('000s), 2002-2010 34

Figure 7: Gastric Cancer Therapeutics Market, Global, Treatment Usage Patterns ('000s), 2002-2010 35

Figure 8: Gastric Cancer, Global, Market Drivers and Restraints, 2009 37

Figure 9: Gastric Cancer Therapeutics Market, Global, Historical Events Impact on the Market, 2010 38

Figure 10: Gastric Cancer Therapeutics Market, Global, Sales Value ($m), 2010-2020 39

Figure 11: Gastric Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 2010-2020 40

Figure 12: Gastric Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2020 41

Figure 13: Gastric Cancer Therapeutics Market, Global, Patient Volume ('000s), 2010-2020 42

Figure 14: Gastric Cancer Therapeutics Market, Global, Treatment Usage Patterns ('000s), 2010-2020 43

Figure 15: Gastric Cancer Therapeutics Market, Global, Future Market Drivers and Restraints, 2010-2020 45

Figure 16: Gastric Cancer Therapeutics Market, Global, Gastric Cancer Drug Sales ($m), 2001-2020 46

Figure 17: Gastric Cancer Therapeutics Market, Global, Breakdown of Drug Sales (%), 2010 49

Figure 18: Gastric Cancer Therapeutics Market, the US, Sales Value ($m), 2002-2010 50

Figure 19: Gastric Cancer Therapeutics Market, the US, Annual Cost of Therapy ($), 2002-2010 51

Figure 20: Gastric Cancer Therapeutics Market, the US, Patient Volume ('000s), 2002-2010 52

Figure 21: Gastric Cancer Therapeutics Market, the US, Treatment Usage Patterns ('000s), 2002-2010 54

Figure 22: Gastric Cancer Therapeutics Market, the US, Market Drivers and Restraints, 2009 56

Figure 23: Gastric Cancer Therapeutics Market, the US, Historical Events Impact on the Market, 2010 58

Figure 24: Gastric Cancer Therapeutics Market, the US, Sales Value ($m), 2010-2020 59

Figure 25: Gastric Cancer Therapeutics Market, the US, Annual Cost of Therapy ($), 2010-2020 60

Figure 26: Gastric Cancer Therapeutics Market, the US, Patient Volume ('000s), 2010-2020 61

Figure 27: Gastric Cancer Therapeutics Market, the US, Treatment Usage Patterns ('000s), 2010-2020 62

Figure 28: Gastric Cancer Therapeutics Market, the US, Future Market Drivers and Restraints, 2010-2020 64

Figure 29: Gastric Cancer Therapeutics Market, the US, Gastric Cancer Drug Sales ($m), 2001-2020 65

Figure 30: Gastric Cancer Therapeutics Market, the UK, Sales Value ($m), 2002-2010 69

Figure 31: Gastric Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2002-2010 71

Figure 32: Gastric Cancer Therapeutics Market, the UK, Patient Volume ('000s), 2002-2010 72

Figure 33: Gastric Cancer Therapeutics Market, the UK, Treatment Usage Patterns ('000s), 2002-2010 73

Figure 34: Gastric Cancer Therapeutics Market, the UK, Market Drivers and Restraints, 2009 75

Figure 35: Gastric Cancer Therapeutics Market, the UK, Historical Events Impact on the Market, 2010 77

Figure 36: Gastric Cancer Therapeutics Market, the UK, Sales Value ($m), 2010-2020 78

Figure 37: Gastric Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2010-2020 79

Figure 38: Gastric Cancer Therapeutics Market, the UK, Patient Volume ('000s), 2010-2020 80

Figure 39: Gastric Cancer Therapeutics Market, the UK, Treatment Usage Patterns ('000s), 2010-2020 81

Figure 40: Gastric Cancer Therapeutics Market, the UK, Future Market Drivers and Restraints, 2010-2020 83

Figure 41: Gastric Cancer Therapeutics Market, the UK, Gastric Cancer Drug Sales ($m), 2002-2020 84

Figure 42: Gastric Cancer Therapeutics Market, Germany, Sales Value ($m), 2002-2010 88

Figure 43: Gastric Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002-2010 90

Figure 44: Gastric Cancer Therapeutics Market, Germany, Patient Volume ('000s), 2002-2010 91

Figure 45: Gastric Cancer Therapeutics Market, Germany, Treatment Usage Patterns ('000s), 2002-2010 92

Figure 46: Gastric Cancer Therapeutics Market, Germany, Market Drivers and Restraints, 2009 94

Figure 47: Gastric Cancer Therapeutics Market, Germany, Historical Events Impact on the Market, 2010 96

Figure 48: Gastric Cancer Therapeutics Market, Germany, Sales Value ($m), 2010-2020 97

Figure 49: Gastric Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2010-2020 98

Figure 50: Gastric Cancer Therapeutics Market, Germany, Patient Volume ('000s), 2010-2020 99

Figure 51: Gastric Cancer Therapeutics Market, Germany, Treatment Usage Patterns ('000s), 2010-2020 100

Figure 52: Gastric Cancer Therapeutics Market, Germany, Future Market Drivers and Restraints, 2010-2020 102

Figure 53: Gastric Cancer Therapeutics Market, Germany, Gastric Cancer Drug Sales ($m), 2002-2020 103

Figure 54: Gastric Cancer Therapeutics Market, France, Sales Value ($m), 2002-2010 107

Figure 55: Gastric Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2002-2010 109

Figure 56: Gastric Cancer Therapeutics Market, France, Patient Volume ('000s), 2002-2010 110

Figure 57: Gastric Cancer Therapeutics Market, France, Treatment Usage Patterns ('000s), 2002-2010 111

Figure 58: Gastric Cancer, France, Market Drivers and Restraints, 2009 113

Figure 59: Gastric Cancer, France, Historical Events Impact on the Market, 2010 114

Figure 60: Gastric Cancer Therapeutics Market, France, Sales Value ($m), 2010-2020 115

Figure 61: Gastric Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2010-2020 116

Figure 62: Gastric Cancer Therapeutics Market, France, Patient Volume ('000s), 2010-2020 117

Figure 63: Gastric Cancer Therapeutics Market, France, Treatment Usage Patterns ('000s), 2010-2020 118

Figure 64: Gastric Cancer Therapeutics Market, France, Future Market Drivers and Restraints, 2010-2020 120

Figure 65: Gastric Cancer Therapeutics Market, France, Gastric Cancer Drug Sales ($m), 2002-2020 121

Figure 66: Gastric Cancer Therapeutics Market, Italy, Sales Value ($m), 2002-2010 125

Figure 67: Gastric Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002-2010 127

Figure 68: Gastric Cancer Therapeutics Market, Italy, Patient Volume ('000s), 2002-2010 128

Figure 69: Gastric Cancer Therapeutics Market, Italy, Treatment Usage Patterns ('000s), 2002-2010 129

Figure 70: Gastric Cancer Therapeutics Market, Italy, Market Drivers and Restraints, 2009 131

Figure 71: Gastric Cancer Therapeutics Market, Italy, Historical Events Impact on the Market, 2010 133

Figure 72: Gastric Cancer Therapeutics Market, Italy, Sales Value ($m), 2010-2020 134

Figure 73: Gastric Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2010-2020 135

Figure 74: Gastric Cancer Therapeutics Market, Italy, Patient Volume ('000s), 2010-2020 136

Figure 75: Gastric Cancer Therapeutics Market, Italy, Treatment Usage Patterns ('000s), 2010-2020 137

Figure 76: Gastric Cancer Therapeutics Market, Italy, Future Market Drivers and Restraints, 2010-2020 139

Figure 77: Gastric Cancer Therapeutics Market, Italy, Gastric Cancer Drug Sales ($m), 2002-2020 140

Figure 78: Gastric Cancer Therapeutics Market, Spain, Sales Value ($m), 2002-2010 144

Figure 79: Gastric Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002-2010 146

Figure 80: Gastric Cancer Therapeutics Market, Spain, Patient Volume ('000s), 2002-2010 147

Figure 81: Gastric Cancer Therapeutics Market, Spain, Treatment Usage Patterns ('000s), 2002-2010 148

Figure 82: Gastric Cancer Therapeutics Market, Spain, Market Drivers and Restraints, 2009 150

Figure 83: Gastric Cancer Therapeutics Market, Spain, Historical Events Impact on the Market, 2010 152

Figure 84: Gastric Cancer Therapeutics Market, Spain, Sales Value ($m), 2010-2020 153

Figure 85: Gastric Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2010-2020 154

Figure 86: Gastric Cancer Therapeutics Market, Spain, Patient Volume ('000s), 2010-2020 155

Figure 87: Gastric Cancer Therapeutics Market, Spain, Treatment Usage Patterns ('000s), 2010-2020 156

Figure 88: Gastric Cancer Therapeutics Market, Spain, Future Market Drivers and Restraints, 2010-2020 158

Figure 89: Gastric Cancer Therapeutics Market, Spain, Gastric Cancer Drug Sales ($m), 2002-2020 159

Figure 90: Gastric Cancer Therapeutics Market, Japan, Sales Value ($m), 2002-2010 163

Figure 91: Gastric Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2010 164

Figure 92: Gastric Cancer Therapeutics Market, Japan, Patient Volume ('000s), 2002-2010 165

Figure 93: Gastric Cancer Therapeutics Market, Japan, Treatment Usage Patterns ('000s), 2002-2010 166

Figure 94: Gastric Cancer Therapeutics Market, Japan, Market Drivers and Restraints, 2009 168

Figure 95: Gastric Cancer Therapeutics Market, Japan, Historical Events Impact on the Market, 2010 169

Figure 96: Gastric Cancer Therapeutics Market, Japan, Sales Value ($m), 2010-2020 170

Figure 97: Gastric Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2010-2020 171

Figure 98: Gastric Cancer Therapeutics Market, Japan, Patient Volume ('000s), 2010-2020 172

Figure 99: Gastric Cancer Therapeutics Market, Japan, Treatment Usage Patterns ('000s), 2010-2020 173

Figure 100: Gastric Cancer Therapeutics Market, Japan, Future Events Expected to Impact the Market, 2010 175

Figure 101: Gastric Cancer Therapeutics Market, Japan, Gastric Cancer Drug Sales ($m), 2001-2020 176

Figure 102: Gastric Cancer Therapeutics Market, Brazil, Sales Value ($m), 2002-2010 180

Figure 103: Gastric Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002-2010 181

Figure 104: Gastric Cancer Therapeutics Market, Brazil, Patient Volume ('000s), 2002-2010 182

Figure 105: Gastric Cancer Therapeutics Market, Brazil, Treatment Usage Patterns ('000s), 2002-2010 183

Figure 106: Gastric Cancer Therapeutics Market, Brazil, Market Drivers and Restraints, 2009 185

Figure 107: Gastric Cancer Therapeutics Market, Brazil, Historical Events Impact on the Market, 2010 186

Figure 108: Gastric Cancer Therapeutics Market, Brazil, Sales Value ($m), 2010-2020 187

Figure 109: Gastric Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2010-2020 188

Figure 110: Gastric Cancer Therapeutics Market, Brazil, Patient Volume ('000s), 2010-2020 189

Figure 111: Gastric Cancer Therapeutics Market, Brazil, Treatment Usage Patterns ('000s), 2010-2020 191

Figure 112: Gastric Cancer Therapeutics Market, Brazil, Future Events Expected to Impact the Market, 2010 193

Figure 113: Gastric Cancer, Russia, Sales Value ($m), 2002-2010 194

Figure 114: Gastric Cancer, Russia, Annual Cost of Therapy ($), 2002-2010 195

Figure 115: Gastric Cancer, Russia, Patient Volume ('000s), 2002-2010 196

Figure 116: Gastric Cancer, Russia, Treatment Usage Patterns, 2002-2010 197

Figure 117: Gastric Cancer Therapeutics Market, Russia, Market Drivers and Restraints, 2009 199

Figure 118: Gastric Cancer Therapeutics Market, Russia, Historical Events Impact on the Market, 2010 200

Figure 119: Gastric Cancer, Russia, Sales Value ($m), 2010-2020 201

Figure 120: Gastric Cancer, Russia, Annual Cost of Therapy ($), 2010-2020 202

Figure 121: Gastric Cancer, Russia, Patient Volume ('000s), 2010-2020 203

Figure 122: Gastric Cancer, Russia, Treatment Usage Patterns, 2010-2020 204

Figure 123: Gastric Cancer Therapeutics Market, Russia, Future Events Expected to Impact the Market, 2010 206

Figure 124: Gastric Cancer, India, Sales Value ($m), 2002-2010 207

Figure 125: Gastric Cancer, India, Annual Cost of Therapy ($), 2002-2010 208

Figure 126: Gastric Cancer, India, Patient Volume ('000s), 2002-2010 209

Figure 127: Gastric Cancer, India, Treatment Usage Patterns, 2002-2010 210

Figure 128: Gastric Cancer Therapeutics Market, India, Market Drivers and Restraints, 2009 212

Figure 129: Gastric Cancer Therapeutics Market, India, Historical Events Impact on the Market, 2010 213

Figure 130: Gastric Cancer, India, Sales Value ($m), 2010-2020 214

Figure 131: Gastric Cancer, India, Annual Cost of Therapy ($), 2010-2020 215

Figure 132: Gastric Cancer, India, Patient Volume ('000s), 2010-2020 216

Figure 133: Gastric Cancer, India, Treatment Usage Patterns, 2010-2020 217

Figure 134: Gastric Cancer Therapeutics Market, India, Future Events Expected to Impact the Market, 2010 219

Figure 135: Gastric Cancer, China, Sales Value ($m), 2002-2010 220

Figure 136: Gastric Cancer, China, Annual Cost of Therapy ($), 2002-2010 221

Figure 137: Gastric Cancer, China, Patient Volume ('000s), 2002-2010 222

Figure 138: Gastric Cancer, China, Treatment Usage Patterns, 2002-2010 223

Figure 139: Gastric Cancer Therapeutics Market, China, Market Drivers and Restraints, 2009 225

Figure 140: Gastric Cancer Therapeutics Market, China, Historical Events Impact on the Market, 2010 226

Figure 141: Gastric Cancer, China, Sales Value ($m), 2010-2020 227

Figure 142: Gastric Cancer, China, Annual Cost of Therapy ($), 2010-2020 228

Figure 143: Gastric Cancer, China, Patient Volume ('000s), 2010-2020 229

Figure 144: Gastric Cancer, China, Treatment Usage Patterns, 2010-2020 230

Figure 145:Gastric Cancer Therapeutics Market, China, Future Events Expected to Impact the Market, 2010 232

Figure 146: Gastric Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, 2011 236

Figure 147: Gastric Cancer Therapeutics Market, Global, Sales Forecast by Therapies, 2001-2020 238

Figure 148: Gastric Cancer, Global, Herceptin, Sales ($m), 2010-2020 241

Figure 149: Gastric Cancer, Globa

To order this report:

: Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 – Volume I 2011

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds North America Neurology Devices Market Outlook to 2017
2. Reportlinker Adds Europe Nephrology and Urology Devices Market Outlook to 2017
3. Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011
4. Reportlinker Adds Continuous Glucose Monitoring (CGM) Systems - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
5. Reportlinker Adds World In Vitro Diagnostics Market
6. Reportlinker Adds Global Market for Medical Devices, 2nd Edition
7. Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries)
8. Reportlinker Adds Asia Pacific Markets for Dental Bone Graft Substitutes and Other Biomaterials 2011
9. Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries)
10. Reportlinker Adds Global: Pharmaceuticals Industry Guide
11. Reportlinker Adds Asian Vaccine Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 27, 2016 , ... Quality metrics are ... in many ways they remain in the eye of the beholder, according to experts ... publication of The American Journal of Managed Care. For the full issue, click ...
(Date:6/26/2016)... Viejo, California (PRWEB) , ... June 26, 2016 , ... ... Final Cut Pro X. , "Film editors can give their videos a whole new ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
Breaking Medicine News(10 mins):